AI
Saturday, August 20, 2016 4:21:18 PM
Gabor my view is that JELIS offers only a loose guide to what to expect in R-IT
I used the LDL levels and sub optimal use of low intensity Statins in JELIS as example of why I expect there to be moderate at best relevance to R-IT ...where we know that patients will be on optimal Statin dose and as a result their LDL levels will be at least half those in JELIS 2ndry .
Reduce It population on optimal dose Statins is also likely to have lower HsCrp levels ....LDL is only one part of it.
JELIS 2ndry is the closest to R-IT we have for guidance . I-IT trial has IMHO little relevance
I would note this tho from NEJM ( reading from different screen so can't link )...re the Improve It trial
" The extent of benefit afforded by the simavastatin -ezetimbe combination is consistent with that seen in previous statin trials , with a similar reduction in cardiovascular events according to the degree of LDL cholesterol lowering " ( hope you don't mind if I do a "Gabor "...highlight in red ...
So if NEJM is to believed ...the event rate in JELIS would have been lower in both arms if both arms had been on optimal Statin dose . Since they weren't, the JELIS 2ndry data is IMHO only a loose guide.
JMO
Kiwi
I used the LDL levels and sub optimal use of low intensity Statins in JELIS as example of why I expect there to be moderate at best relevance to R-IT ...where we know that patients will be on optimal Statin dose and as a result their LDL levels will be at least half those in JELIS 2ndry .
Reduce It population on optimal dose Statins is also likely to have lower HsCrp levels ....LDL is only one part of it.
JELIS 2ndry is the closest to R-IT we have for guidance . I-IT trial has IMHO little relevance
I would note this tho from NEJM ( reading from different screen so can't link )...re the Improve It trial
" The extent of benefit afforded by the simavastatin -ezetimbe combination is consistent with that seen in previous statin trials , with a similar reduction in cardiovascular events according to the degree of LDL cholesterol lowering " ( hope you don't mind if I do a "Gabor "...highlight in red ...
So if NEJM is to believed ...the event rate in JELIS would have been lower in both arms if both arms had been on optimal Statin dose . Since they weren't, the JELIS 2ndry data is IMHO only a loose guide.
JMO
Kiwi
